

Reference Number: FOI202223/460
From: Private Individual
Date: 12 December 2022
Subject: Incidence and treatment of Haemophilia A

Q1 How many patients are registered with your Haemophilia Centre for:

- a. Haemophilia A
- b. Haemophilia A – severe disease
- c. Haemophilia A – moderate disease
- d. Haemophilia A – mild disease

A1 Information not held – the Trust does not routinely collate or hold this information centrally as part of its management or performance data. In order to confirm treatment following medication being dispensed, the Trust would be required to access personal data of the individuals and as such the data is exempt under Section 40: Personal data.

Q2 In the last three months, how many patients have been treated by your haemophilia centre with the following products?

- a. Advate
- b. Adynovi
- c. Elocta
- d. Esperoct
- e. Factor Eight Inhibitor Bypass Activity (FEIBA)
- f. Hemlibra (standalone)
- g. Hemlibra in combination with any Factor VIII
- h. NovoEight
- i. NovoSeven RT
- j. Obizur
- k. Refacto AF

A2 Information not held – the Trust does not routinely collate or hold this information centrally as part of its management or performance data. In order to confirm treatment following medication being dispensed, the Trust would be required to access personal data of the individuals and as such the data is exempt under Section 40: Personal data.

Q3 In the last three months, how many patients were treated with the following products for severe Haemophilia A ONLY?

- a. Advate
- b. Adynovi
- c. Elocta
- d. Esperoct
- e. Factor Eight Inhibitor Bypass Activity (FEIBA)
- f. Hemlibra (standalone)
- g. Hemlibra in combination with any Factor VIII
- h. NovoEight
- i. NovoSeven RT
- j. Obizur
- k. Refacto AF

A3 Information not held – the Trust does not routinely collate or hold this information centrally as part of its management or performance data. In order to confirm treatment following medication being dispensed, the Trust would be required to access personal data of the individuals and as such the data is exempt under Section 40: Personal data.